middle.news
Prescient Therapeutics Doses First Patient in Pivotal PTX-100 CTCL Trial
1:36am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Prescient Therapeutics Doses First Patient in Pivotal PTX-100 CTCL Trial
1:36am on Monday 2nd of June, 2025 AEST
Key Points
First patient dosed in Phase 2a PTX-100 trial for CTCL
Study targets up to 40 patients across Australia, USA, and Europe
PTX-100 holds FDA orphan drug and fast track designations
Trial focuses on relapsed/refractory Cutaneous T-Cell Lymphoma
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE